Tags : o2h Ventures

Female Led

Monument Therapeutics secures £2.625 million Seed investment led by Catapult

Digital brain biomarker company Monument Therapeutics raises £2.6 million Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction  Manchester, UK, August 2021: Monument Therapeutics, a stratified medicine company, has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying […]Read More

Seed

Kuano secures £1 million Seed investment from investors including ACF

Kuano.ai raises £1m seed to de-risk and accelerate drug discovery using artificial intelligence and quantum computing The funding will go towards further development of its platform for generating better enzyme inhibitors London, 8 July 2021 – Kuano.ai, a software platform for rapid, cost effective quantum modelling of enzymes, has raised £1 million in seed funding […]Read More

Original

PhoreMost secures £33 million Series B investment led by BGF

PhoreMost closes £33M ($46M) Series B financing Funding to support progression of PLK1 program, for treatment of brain cancer, into the clinic within 18 months Company is advancing its pipeline of novel therapies for oncology and diseases of ageing, and developing novel therapeutic modalities in the targeted protein degradation space Oversubscribed investment round led by BGF, […]Read More

AI/ML

PharmEnable secures £1.8 million Seed investment led by Cambridge Enterprise

Cambridge Spin-out PharmEnable Raises £1.8 million for Drug Discovery Expansion £1.8m seed financing led by Cambridge Enterprise alongside angel investors and life science investment funds Using advanced medicinal chemistry and AI approaches to develop highly complex and specific drug candidate molecules Will enable in-house drug discovery across a number of therapeutic areas including cancer and […]Read More

Original

Qkine secures £1.5 million Series A investment led by Parkwalk

Qkine secures £1.5M series A funding from leading life science investors to accelerate global scale-up and make key hires to leadership team Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round […]Read More

Series A

Oxford Drug Design secures £2.2 million Series A investment from

Oxford Drug Design wins UK-China AMR grant and boosts funding with investment from the Angel CoFund  Oxford University biotech spin-out receives over £2 million to take its drug discovery programme to the next level Oxford, 5th November 2019 – Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised a […]Read More